These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 36204323)

  • 21. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer.
    Wang Q; Xu Y
    Front Pharmacol; 2022; 13():1065701. PubMed ID: 36532719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma.
    Xu QS; Shen ZZ; Yuan LQ
    Front Cell Dev Biol; 2022; 10():968590. PubMed ID: 36467424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
    Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
    Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
    Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
    Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
    Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
    Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
    Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
    Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer.
    Xu R; Wu X; Du A; Zhao Q; Huang H
    Am J Cancer Res; 2022; 12(11):5241-5254. PubMed ID: 36504883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
    Front Genet; 2022; 13():947551. PubMed ID: 35938003
    [No Abstract]   [Full Text] [Related]  

  • 32. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis.
    Yin C; Gao M; Wang Q; Li H
    Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
    Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
    Front Genet; 2023; 14():1096783. PubMed ID: 36911392
    [No Abstract]   [Full Text] [Related]  

  • 34. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
    Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
    Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
    Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
    Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma.
    Wu J; Yao J; Jia S; Yao X; Shao J; Cao W; Ma S; Yao X; Li H
    Heliyon; 2023 Sep; 9(9):e19352. PubMed ID: 37810122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer.
    Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y
    Front Genet; 2022; 13():984743. PubMed ID: 36467996
    [No Abstract]   [Full Text] [Related]  

  • 38. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [No Abstract]   [Full Text] [Related]  

  • 39. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
    Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
    Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction of a cuproptosis-related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients.
    Ni S; Hong J; Li W; Ye M; Li J
    Cancer Med; 2023 Feb; 12(4):5009-5024. PubMed ID: 36129020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.